<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647177</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-14-0980</org_study_id>
    <nct_id>NCT02647177</nct_id>
  </id_info>
  <brief_title>A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions</brief_title>
  <official_title>A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose To determine the diagnostic potential of various biological markers in blood and&#xD;
      cyst fluid aspirates from patients with Pancreatic Cystic Lesions (PCLs).&#xD;
&#xD;
      Research design This is a 10-year prospective cohort and pancreatic cyst fluid repository&#xD;
      study enrolling all patients diagnosed with pancreatic cyst and undergoing the cyst&#xD;
      aspiration.&#xD;
&#xD;
      Procedures to be used Blood Sample Cyst Fluid Sample&#xD;
&#xD;
      Data Collection:&#xD;
&#xD;
      Medical Record Number Demographics (age, sex, gender, race) Contact information History of&#xD;
      alcohol use and IV and other recreational drugs and narcotics use/abuse Medication history&#xD;
      Past hospitalizations, diagnoses, and treatment Physical examination findings Imaging data of&#xD;
      abdominal and chest regions, including and not limited to ultrasonography, magnetic resonance&#xD;
      imaging (MRI), computed tomography (CT) Future admissions, diagnoses, treatment including&#xD;
      histopathological findings of resected specimens and blood reports End of study data:&#xD;
      clinical progression of disease, cyst size, wall thickening, calcification, communication&#xD;
      with pancreatic duct, string sign, cytology, immunohistochemical findings, assay levels of&#xD;
      lipase, amylase CEA (carcinoembryonic antigen), carbohydrate antigen19-9 (CA 19-9), and other&#xD;
      biomarkers.&#xD;
&#xD;
      Risks and potential benefits The risks associated with this study are slight discomfort or&#xD;
      bruising from the blood sampling and the possible loss of confidentiality if the patient data&#xD;
      or information is inadvertently disclosed outside of this study. The patient will not receive&#xD;
      any additional benefit from the study aside from those received as part of routine standard&#xD;
      of care.&#xD;
&#xD;
      Importance of knowledge that may reasonably be expected to result The knowledge gained from&#xD;
      this study may benefit other patients with Pancreatic Cyst Lesions in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">April 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Detection of early progression to Tumor</measure>
    <time_frame>2 years</time_frame>
    <description>To identify any correlation between higher expression levels with early progression to malignant changes in the pancreas</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Pancreatic Cystic Lesions</condition>
  <arm_group>
    <arm_group_label>Pancreatic Cyst Group</arm_group_label>
    <description>Only the eligible participant in the study are considered for inclusion in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pancreatic Cyst Aspiration</intervention_name>
    <description>10 CC of pancreatic cyst aspiration</description>
    <arm_group_label>Pancreatic Cyst Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cyst aspirate&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to Memorial Hermann Hospital for care with the primary and&#xD;
        subinvestigator(s) of the study will be identified, prescreened for eligibility and listed&#xD;
        for informed consent and subsequent enrollment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Pancreatic Cystic Lesions (PCLs) or Acute Pancreatitis (AP) or chronic&#xD;
             pancreatitis(CP) or Pacreatic Cancer (PC) (any stage/grade) or congenital&#xD;
             developmental anomalies of the pancreas.&#xD;
&#xD;
          -  Any combination of the diagnoses above.&#xD;
&#xD;
          -  Patients must provide written informed consent for the collection of blood specimens&#xD;
             for research purposes.&#xD;
&#xD;
          -  Patients with PCLs must provide informed consent for collection of excess cyst fluid&#xD;
             aspirate remaining after testing for routine standard of care&#xD;
&#xD;
          -  Patients with pancreatic Cystic Lesions (PCLs) or AP or CP or PC (any stage/grade) or&#xD;
             congenital developmental anomalies of the pancreas undergoing surgery must provide&#xD;
             informed consent for collection of surgical specimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with co-existing malignancies of other organs (or prior history of such)&#xD;
&#xD;
          -  Patients unable to provide informed consent&#xD;
&#xD;
          -  Patients unable to complete follow up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nirav C Thosani, MD MHA</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prithvi Patil, MS</last_name>
    <phone>(713) 500-6654</phone>
    <email>prithvi.b.patil@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Priyanka Priyanka, BAMS, MPH</last_name>
    <phone>7135006457</phone>
    <email>priyanka.priyanka@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bijun Kannadath, MBBS</last_name>
      <phone>713-500-6654</phone>
      <email>bijun.s.kannadath@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Nirav C Thosani</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Cyst</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

